<DOC>
	<DOCNO>NCT01207440</DOCNO>
	<brief_summary>The purpose study determine efficacy ponatinib patient chronic myeloid leukemia ( CML ) chronic phase ( CP ) , accelerate phase ( AP ) blast phase ( BP ) Ph positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) either resistant intolerant either dasatinib nilotinib , T315I mutation .</brief_summary>
	<brief_title>Ponatinib Chronic Myeloid Leukemia ( CML ) Evaluation Ph+ Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>The preliminary analysis phase 1 clinical trial reveal evidence clinical antitumor activity patient resistance approve second-generation tyrosine kinase inhibitor ( TKI ) , dasatinib nilotinib , include patient T315I mutation BCR-ABL gene ( BCR-ABL ) . This Phase 1 study , take together strong preclinical data characterize ponatinib , provide rationale move pivotal phase 2 trial agent population patient chronic myeloid leukemia ( CML ) Ph+ Acute Lymphoblastic Leukemia ( ALL ) resistant intolerant prior TKI therapy patient T315I mutation . PACE multi-center , international , phase 2 , uncontrolled , open-label trial oral ponatinib patient Philadelphia chromosome-positive ( Ph+ ) disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>Patients must CML phase ( CP , AP , BP phenotype ) Ph+ ALL Previously treat developed resistance intolerance dasatinib nilotinib OR develop T3151 mutation tyrosine kinase inhibitor ( TKI ) therapy ≥18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Minimum life expectancy ≥3 month Adequate kidney function Adequate liver function Normal pancreatic function Normal QT Fridericiacorrected interval ( QTcF ) ≤450 ms male ≤470 ms female Negative pregnancy test ( woman childbearing potential ) Agree use effective form contraception ( applicable ) Ability comply study procedure , Investigator 's opinion Received prior TKI treatment within 7 day prior receive first dose ponatinib , recover adverse event ( except alopecia ) due agent previously administer . Received therapy follow : 1 . For CML chronic phase ( CP ) accelerate phase ( AP ) patient , receive hydroxyurea anagrelide within 24 hour prior receive first dose ponatinib ; interferon , cytarabine , immunotherapy within 14 day prior first dose ponatinib ; cytotoxic chemotherapy , radiotherapy , investigational therapy within 28 day prior receive first dose ponatinib . 2 . For CML blast phase ( BP ) patient , receive chemotherapy within 14 day prior first dose ponatinib . 3 . For Ph+ ALL patient , receive corticosteroid within 24 hour first dose ponatinib ; vincristine within 7 day prior first dose ponatinib ; receive chemotherapy within 14 day prior first dose ponatinib . Underwent stem cell transplant &lt; 60 day prior receive first dose ponatinib Evidence ongoing graft versushost disease ( GVHD ) , GVHD require immunosuppressive therapy Taking medication know associated Torsades de Pointes Require concurrent treatment immunosuppressive agent ( corticosteroid prescribe short course therapy ) Previously treat ponatinib CML CP patient exclude Complete cytogenetic response ( CCyR ) Patients CML AP , CML BP , Ph+ ALL exclude Major Hematologic Response ( MaHR ) . Have active Central Nervous System ( CNS ) disease Have significant active cardiovascular disease Have significant bleed disorder unrelated CML Ph+ALL Have history pancreatitis alcohol abuse Have uncontrolled hypertriglyceridemia ( triglyceride &gt; 450 mg/dL ) Have malabsorption syndrome gastrointestinal illness could affect absorption ponatinib Diagnosed another primary malignancy past 3 year Pregnant lactate Underwent major surgery within 14 day prior first dose ponatinib Have ongoing active infection Suffer condition illness would compromise safety interfere evaluation drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>ALL</keyword>
	<keyword>PH</keyword>
	<keyword>ponatinib</keyword>
	<keyword>Ph+ALL</keyword>
	<keyword>T315I mutation</keyword>
	<keyword>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</keyword>
</DOC>